Phase
Condition
Rectal Cancer
Colon Cancer
Colorectal Cancer
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients with colorectal cancer meeting one of the following criteria: 1. naive tooxaliplatin or to any microtubule stabilizing agents (e.g. Taxol, Abraxane,Ixabepilone) but scheduled for combined oxaliplatine chemotherapy (longitudinal studycohort 1); or 2. during first 5 years from colorectal cancer diagnosis (cross-sectional study cohort). This second cohort may include patients withcolorectal cancer from the original 12-month study (the longitudinal cohort), boththose who completed the study and those who dropped out. It may also include newpatients who did not participate in the longitudinal phase of the study.
Patients >= 18 years old.
Patients who speak English or Spanish.
Exclusion
Exclusion Criteria:
Cohort 1 patients with a neuropathy score of 1 or greater on the NCI's CommonTerminology Criteria (CTCv3.0).
Patients who do not understand the intent of the study.
Cohort 1 patients unable to use the interactive voice response (IVR) system due tophysical limitations (e.g., hearing impairment).
Cohort 1 patients with a history of inflammatory bowel disease.
Study Design
Study Description
Connect with a study center
University of Texas MD Anderson Cancer Center
Houston, Texas 77030
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.